Anti-allodynic effects of a novel quinazolin-4-3H--ones derivative- 2--2-methyl-4-oxoquinazolin-3-4H--yl--N-p-tolylacetamide -P-TOL- in CCI and SNL induced neuropathic pain in rats-

S.M. Ahmed, U.C. Devidas

Faculty of pharmacy, Shri Neminath Jain Bramhacharyashram's Shriman Sureshdada Jain College of Pharmacy Jain Gurukul, Chandwad, India

International Journal of Scientific & Engineering Research

Quinazoline-4(3H)-ones and its derivatives are versatile nitrogen heterocyclic compounds and exhibit potent activities like analgesic and anti-inflammatory. Here we have investigated anti-allodynic potentials of some of the newly synthesized Quinazolines derivative. Pharmacological activity was evaluated in the rodent models of neuropathic pain (Chronic constriction injury and spinal nerve ligation). The compound T-02 (P-Tol) demonstrated good activity in neuropathic pain models. In Chronic constriction injury (CCI) the loose ligation of the sciatic nerve model, the compound T-02 (P-Tol) shows the significant effect at doses 3 mg/kg and 10 mg/kg when administered orally. The standard Gabapentin also shows the significant reduction in pain at dose 150 mg/kg after the oral administration. In spinal nerve ligation (SNL), the tight ligation to the L5 and L6 nerve, the compound T-02 (P-Tol) after oral administration we have not seen any significant reduction at low dose 1 mg/kg and 3 mg/kg. But at high dose 10 mg/kg compound shows the significant reduction in pain. The standard Gabapentin also shows the significant effect at dose 150 mg/kg. The results in present study demonstrate that the compound shows the remarkable effect on neuropathic pain. The effect of compound in CCI model shows more significant as compare to the SNL model of neuropathic pain. This may be due to the sensitivity produced by nerve damage.

BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)

Related products

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.